Human Plasma and Recombinant Hemopexins: Heme Binding Revisited

Area of Science:

• Biochemistry
• Protein Engineering
• Biophysics

Background:

• Plasma hemopexin (HPX) is crucial for clearing toxic heme during hemolysis.
• Declining HPX levels during intravascular hemolysis necessitate therapeutic interventions.
• Recombinant HPX (rhHPX) production offers a strategy for enhanced therapeutic yields.

Purpose of the Study:

• To biophysically characterize heme binding to rhHPX produced in Expi293F cells.
• To compare the structural and functional properties of rhHPX with plasma-derived HPX.
• To establish an analytical platform for assessing HPX-heme interactions.

Main Methods:

• UV/Vis absorption spectroscopy
• Circular dichroism (CD) spectroscopy
• Size-exclusion chromatography (SEC)-HPLC
• Catalase activity assays
• Heme titration experiments

Main Results:

• rhHPX exhibited structural and functional similarities to plasma HPX.
• CD spectroscopy revealed distinct heme-binding patterns, suggesting multiple binding sites in both forms.
• Heme titration data modeled physiological conditions, demonstrating rhHPX's capacity to bind heme across a wide concentration range.
• rhHPX demonstrated comparable catalase-like activity to plasma HPX.

Conclusions:

• rhHPX is a structurally and functionally comparable alternative to plasma HPX.
• The study confirms rhHPX's potential as a therapeutic agent for hemolytic disorders.
• A robust analytical method for characterizing HPX-heme interactions was established, enabling future development of HPX fusion constructs.